16 presentations will examine safety and efficacy of AJOVY and AUSTEDOTEL AVIV, Israel & PARSIPPANY, N.J. (BUSINESS WIRE) Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data for two of the company’s neurology portfolio treatments, AJOVY® (fr.
Phase 3 trial reached primary endpoint and demonstrated a reduction in SARS-CoV-2 log viral load in COVID-19 patients by more than 94% within 24 hours of treatment, and by more than 99% in 48 hours
Phase 3 trial reached primary endpoint and demonstrated a reduction in SARS-CoV-2 log viral load in COVID-19 patients by more than 94% within 24 hours of treatment, and by more than 99% in 48 hoursTreatment also demonstrated, in the high-risk group (n=218), a greater proportion of patients who achieved a combination.
Phase III POLARIX trial showed Polivy plus R-CHP was the first treatment in two decades to significantly improve outcomes in newly diagnosed diffuse large B-cell lymphoma (DLBCL) versus the standard of
Numerous oral presentations highlighting data for tafasitamab, parsaclisib, ruxolitinib, pemigatinib, itacitinib and ponatinib to be highlighted during the Congress Incyte (Nasdaq:INCY) today announced